Browse the evidence

Time-restricted feeding does not significantly improve cardiometabolic markers (HDL, LDL, triglycerides) compared to control diets in overweight or obese adults.

Do not expect time-restricted feeding to automatically improve your cholesterol or triglyceride levels. While it helps with weight loss, you may need to focus on other dietary factors or exercise to improve your lipid profile.

Chronic inflammation driven by macrophage infiltration into white adipose tissue (WAT) is a primary causal mechanism for obesity-induced insulin resistance, rather than merely a correlative symptom.

In obesity, fat tissue becomes inflamed due to macrophage infiltration, which actively blocks insulin from working properly. This is a biological defense mechanism, not just a passive result of having extra fat. Treating the underlying inflammation (e.g., via medications like TZDs shown in the study) may improve insulin sensitivity independently of immediate weight loss.

Diet-induced obesity causes adipose tissue macrophages (ATMs) to switch from an anti-inflammatory M2 phenotype to a pro-inflammatory M1 phenotype, which drives insulin resistance.

This research highlights that obesity triggers an immune response in fat tissue that actively blocks insulin action. While this paper focuses on mice, it suggests that reducing inflammation in fat tissue (potentially through weight loss, exercise, or anti-inflammatory diets) may be crucial for restoring insulin sensitivity, not just reducing calorie intake.

Hypoadiponectinemia (low plasma adiponectin) in obesity and type 2 diabetes is primarily driven by insulin resistance and hyperinsulinemia rather than adiposity (body fat percentage) alone.

If you have low adiponectin, focusing solely on weight loss may not restore levels if insulin resistance persists. Prioritize interventions that improve insulin sensitivity (like resistance training and carbohydrate management) as these are more strongly correlated with healthy adiponectin levels than body fat percentage alone.

Elevated plasma free fatty acid (FFA) concentrations cause a dose-dependent inhibition of insulin-stimulated glucose uptake in skeletal muscle, primarily by reducing glycogen synthesis and secondarily by reducing carbohydrate oxidation.

High levels of free fatty acids in your blood can block insulin from helping your muscles take up glucose. This happens through two main pathways: it stops your muscles from storing glucose as glycogen and reduces the amount of glucose you burn for energy. This effect is dose-dependent, meaning higher fat levels lead to greater insulin resistance. For healthy individuals, this suggests that managing fat metabolism is crucial for maintaining insulin sensitivity.

Elevated plasma free fatty acids (FFA) and/or glycerol increase hepatic glucose output (HGO) by approximately 50%, contributing to hepatic insulin resistance.

High levels of fat in your blood can cause your liver to produce more glucose, even when you are trying to lower blood sugar. This happens because fat and its byproduct, glycerol, interfere with insulin's ability to stop the liver from making glucose. This contributes to higher blood sugar levels and insulin resistance.

High plasma FFA concentrations impair muscle glycogen synthase (GS) activity, but this impairment occurs late (after 4-6 hours) and is associated with increased glucose-6-phosphate levels.

High levels of fat in your blood can eventually impair the enzyme that helps store glucose as glycogen in your muscles. However, this effect takes several hours to develop and requires high fat levels.

Medium plasma FFA concentrations reduce glycogen synthesis by impairing glucose transport or phosphorylation, leading to decreased glucose-6-phosphate levels, before glycogen synthase activity is affected.

Even moderate levels of fat in your blood can interfere with how your muscles take up and process glucose, before they affect the enzyme that stores it as glycogen. This happens by reducing the amount of glucose-6-phosphate, a key intermediate.

Obesity causes insulin resistance primarily through the expansion of adipose tissue mass, which acts as an endocrine organ secreting factors like TNF-alpha, FFAs, and leptin that impair insulin signaling in muscle and liver.

Focus on reducing central adiposity, as intra-abdominal fat is more metabolically harmful than peripheral fat. This involves addressing the endocrine function of fat tissue, not just weight loss, by managing factors like free fatty acid flux and inflammatory cytokines.

Adipose tissue acts as an endocrine organ, secreting hormones like leptin and cytokines like TNF-alpha, which directly impair insulin signaling in peripheral tissues.

Understand that fat tissue is biologically active. Reducing fat mass helps by reducing the secretion of harmful hormones and cytokines, thereby improving insulin sensitivity.

Early combination therapy with metformin, a thiazolidinedione (TZD), and a GLP-1 receptor agonist (exenatide) is required to correct the multiple pathophysiological defects of type 2 diabetes and preserve beta-cell function, whereas sulfonylureas should be avoided due to progressive beta-cell failure.

If you have type 2 diabetes or pre-diabetes (IGT), waiting until your blood sugar is high to treat it is too late. The paper argues you should start a combination of lifestyle changes, metformin, a TZD (like pioglitazone), and a GLP-1 agonist (like exenatide) early. Avoid sulfonylureas as they harm your pancreas over time. The goal is to protect your beta-cells, not just lower a number.

Beta-cell function is lost by 80-85% in individuals with Impaired Glucose Tolerance (IGT), meaning significant damage occurs long before a formal diabetes diagnosis.

If you have 'pre-diabetes' (IGT), you have likely already lost 80% of your pancreas's ability to make insulin. This is not a 'wait and see' condition. You need to act now to preserve what function remains.

Early and aggressive LDL cholesterol lowering in Familial Hypercholesterolemia (FH) patients significantly reduces cumulative LDL burden and prevents premature coronary heart disease (CHD).

If you or your child has Familial Hypercholesterolemia (FH), do not wait for symptoms. Start maximal statin therapy immediately upon diagnosis to lower LDL cholesterol to specific targets (e.g., <100 mg/dL for adults). This prevents the cumulative damage that leads to heart attacks in your 30s or 40s. Combine medication with lifestyle changes (diet, exercise, no smoking).

In humans, insulin resistance in muscle is primarily caused by intracellular accumulation of fatty acid metabolites (diacylglycerol, ceramides) which activate serine/threonine kinases (e.g., PKC-theta), leading to impaired insulin signaling and reduced glucose transport, rather than by the Randle glucose-fatty acid cycle mechanism.

Insulin resistance in muscle is driven by lipid intermediates like diacylglycerol interfering with insulin signaling, not just by fat oxidation. Managing this involves improving how the body partitions fat away from muscle and liver, potentially through agents that promote adipocyte differentiation or improve mitochondrial fatty acid metabolism.

Nonalcoholic fatty liver disease (NAFLD) is characterized by significant hepatic and peripheral insulin resistance, independent of obesity or glucose tolerance, effectively making it a feature of the metabolic syndrome.

If you have NAFLD, even if you are not overweight or have normal blood sugar, your body likely processes insulin poorly. This insulin resistance is a key driver of the liver condition and places you in the metabolic syndrome category, requiring attention to metabolic health beyond just weight management.

Insulin resistance directly causes cardiovascular disease through three primary mechanisms: signal transduction alteration, impaired substrate metabolism regulation, and altered substrate delivery to the myocardium.

If you have insulin resistance (often associated with obesity or type 2 diabetes), you are at higher risk for heart disease regardless of your cholesterol levels. Addressing insulin sensitivity through lifestyle changes is critical for heart health.

Insulin resistance leads to endothelial dysfunction by selectively impairing nitric oxide (NO) production while activating pro-inflammatory and pro-thrombotic pathways, contributing to hypertension and atherosclerosis.

Insulin resistance damages the lining of your blood vessels (endothelium) by reducing nitric oxide production. This leads to higher blood pressure and increased risk of heart disease. Improving insulin sensitivity helps protect your blood vessels.

Metabolic endotoxaemia, characterized by elevated circulating lipopolysaccharides (LPS) due to increased gut permeability, drives low-grade chronic inflammation associated with type 2 diabetes, NAFLD, and obesity.

High-fat diets can increase gut permeability, allowing lipopolysaccharides (LPS) from Gram-negative bacteria to enter the bloodstream. This triggers a low-grade inflammatory response via Toll-like receptors, contributing to insulin resistance and metabolic diseases like type 2 diabetes and NAFLD. Managing fat intake and supporting gut barrier integrity are key to reducing this inflammatory burden.

Faecal Microbiota Transplantation (FMT) from lean donors to individuals with metabolic syndrome can significantly increase insulin sensitivity and butyrate production, establishing a causal link between microbiota composition and host glucose homeostasis.

FMT from lean donors is a potent intervention for improving insulin sensitivity in metabolic syndrome, primarily by boosting butyrate-producing bacteria. It is currently a medical procedure, not a consumer product.

Gut dysbiosis, characterized by reduced bacterial diversity and butyrate production, contributes to the pathogenesis of liver diseases (NAFLD, NASH, Alcoholic Liver Disease, PSC) through the translocation of bacterial products (endotoxins) to the liver, triggering inflammation.

Maintaining gut barrier integrity and microbial diversity is crucial for liver health. Probiotics and dietary fiber may help reduce liver inflammation by preventing the translocation of bacterial endotoxins to the liver.

AdipoQ (adiponectin) mRNA expression is significantly down-regulated in adipose tissue from obese humans and obese mice compared to lean controls.

This paper identifies that adiponectin (AdipoQ) levels drop significantly in obesity. While this paper does not offer a treatment, it establishes that obesity is associated with a specific hormonal deficit, suggesting that restoring these levels might be a therapeutic target.

Diet-induced weight loss triggers a significant increase in 24-hour plasma ghrelin levels, acting as a hormonal adaptive response to energy deficit.

When you lose weight through dieting, your body biologically fights back by increasing ghrelin, a hormone that drives hunger. This is a normal adaptive response, not a failure of willpower. Expect increased hunger as a physiological signal of your energy deficit.

Gastric bypass surgery results in abnormally low plasma ghrelin levels and the loss of normal meal-related ghrelin fluctuations, which may contribute to sustained weight loss.

Gastric bypass surgery uniquely suppresses ghrelin, the hunger hormone, and eliminates its normal meal-time spikes. This hormonal suppression, rather than just stomach size reduction, helps explain why patients often feel less hungry and maintain weight loss better than with dieting alone.

Obesity-induced expansion of white adipose tissue leads to local hypoxia, which triggers the transcription factor HIF-1 and subsequent secretion of pro-inflammatory adipokines (e.g., TNF-alpha, IL-6, PAI-1), contributing to insulin resistance and metabolic syndrome.

This research suggests that as fat tissue grows, it can outgrow its blood supply, creating low-oxygen conditions that trigger inflammation. This inflammation worsens insulin resistance. Therefore, interventions that reduce fat mass or improve vascular health in adipose tissue may help break this cycle of inflammation and metabolic dysfunction.